Dr. Gornet

Dr. Gornet was born in St. Louis, Missouri. He graduated Summa Cum Laude and Phi Beta Kappa from Washington University in St. Louis in 1982. He was also on the MORTAR Honary Band.

He then attended Medical School at Washington University School of Medicine in St. Louis and graduated in 1986. He received The Southern Medical Association Scholarship and received Academic Honors in Oncology while attending medical school.

Postgraduate training included an Internship in Internal Medicine at the University of California in Los Angeles, residencies in Radiation Oncology at the MD Anderson Cancer Center and the University of Minnesota completed in 1990. He was Chief Resident in Radiation Oncology at the University of Minnesota.

This was followed by a position as a Staff Radiation Oncologist at the Arthur Temple Cancer Center at the Memorial Hospital of East Texas in Luftin, Texas between 1990 and 1991. He then became Medical Director of Radiation Oncology at the St. Francis Hospital in Greenville, South Carolina.

In 1994 Dr. Gornet pursued a Residency in Internal Medicine and following that a Fellowship in Hematology-Oncology at the Mayo Clinic in Rochester between 1994 and 2000.

He then joined the staff at Mayo Clinic Arizona were he achieved the rank of Associate Professor. He joined Palo Verde Hematology Oncology in January of 2008. He is Board Certified in Internal Medicine, Hematology and Oncology.

In his free time he enjoys Golfing, tennis, mountain biking and baseball.

His publications are:

Peer-reviewed Articles

  1. Gornet MK, Buckner JC, Marks RS, Scheithauer BW, Erickson BJ. Chemotherapy for advanced CNS ependymoma. J Neurooncol 1999; 45(1):61-7.
  2. Anderson PM, Markovic SN, Sloan JA, Clawson ML, Wylam M, Arndt CA, Smithson WA, Burch P, Gornet M, Rahman E. Aerosol granulocyte macrophage-colony stimulating factor: a low toxicity, lung-specific biological therapy in patients with lung metastases. Clin Cancer Res 1999 Sep; 5(9):2316-23.
  3. Xiong YN, Donovan KA, Kline MP, Gornet MK, Moon-Tasson LL, Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Lust JA. Identification of two groups of smoldering multiple myeloma patients who are either high or low producers of interleukin-1. J Interferon Cytokine Res 2006 Feb; 26(2):83-95.
  4. Olmedo JM, Yiannias JA, Windgassen EB, Gornet MK. Scurvy: a disease almost forgotten. Int J Dermatol 2006 Aug; 45(8):909-13.

Abstracts and Letters

  1. Donovan KA, Kline MP, Gornet MK, Moon-Tasson LL, Ahmann GJ, Lust JA. Both mature IL-1-beta and proil-1-beta upregulate ICAM-1 (CD54) on marrow stromal cells in myeloma. Blood 1998; 92(10 Suppl 1 Part 1-2):636a.
  2. Anderson P, Clawson M, Wylam M, Arndt C, Smithson W, Markovic SN, Burch P, Gornet M, Sloan JA. Aerosol GM-CSF: a low toxicity, lung specific, biologic therapy, in patients with lung metastases. (Abstract 1734). Program/Proc Am Soc Clin Oncol 1999; 18:449a.
  3. Gornet MK, Galanis E, Frytak S, McElroy E. Merkel cell carcinoma: The Mayo Clinic experience. (Abstract). Proc ASCO. 20:64a, 2001.
  4. Donovan KA, Gornet MK, Moon-Tasson LL, Dahlgren GR, Greipp PR, Kyle RA, Lust JA. Stromal cell interleukin-6 (IL-6) production differentiates monoclonal gammopathy of undetermined significance (MGUS) from multiple myeloma: Importance of interleukin-1beta (IL-1beta). Blood 2001 Nov 16; 98(11 Part 2):297b.
  5. Donovan KA, Gornet MK, Xiong Y, Lacy MQ, Moon-Tasson LL, Dahlgren GR, Kyle RA, Therneau TM, Greipp PR, Lust JA. Stromal cell interleukin-6 (IL-6) production and percent plasma cells predict progression of smoldering multiple myeloma (SMM) to multiple myeloma (MM): importance of the IL-1beta/IL-6 axis in myeloma pathogenesis (Abstract 383). Blood 2002; 100(11).
  6. Rao RD, Windschitl HE, Allred JB, Lowe VJ, Maples WJ, Gornet MK, Suman VJ, Creagan ET, Pitot HC, Markovic SN. Phase II trial of the mTor inhibitor everolimus (RAD-001) in metastatic melanoma (Abstract 8043). J Clin Oncol 2006 Jun; 24(Suppl 18S):463s.
  7. Griffing WL, Mazlumzadeh M, Harmon CE, Northfelt DW, Gornet MK. Aromatase inhibitor-associated tenosynovitis: a new entity? (Abstract 1614). Arthritis & Rheumatism 2006 Sep; 54(9 Suppl):S650.